DB:366

Stock Analysis Report

Executive Summary

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has AzurRx BioPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 366's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.3%

366

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-21.2%

366

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 366 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 366 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

366IndustryMarket
7 Day5.3%-2.3%-0.2%
30 Day-13.6%-3.2%0.3%
90 Day39.1%6.3%3.7%
1 Year-21.2%-21.2%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is AzurRx BioPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AzurRx BioPharma undervalued compared to its fair value and its price relative to the market?

7.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 366's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 366's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 366 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 366 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 366's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 366 is overvalued based on its PB Ratio (7.7x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is AzurRx BioPharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

30.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 366 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 366 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 366 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 366's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 366's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 366's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AzurRx BioPharma performed over the past 5 years?

-25.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 366 is currently unprofitable.

Growing Profit Margin: 366 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 366 is unprofitable, and losses have increased over the past 5 years at a rate of -25% per year.

Accelerating Growth: Unable to compare 366's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 366 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 366 has a negative Return on Equity (-559.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AzurRx BioPharma's financial position?


Financial Position Analysis

Short Term Liabilities: 366's short term assets ($3.7M) do not cover its short term liabilities ($5.8M).

Long Term Liabilities: 366's short term assets ($3.7M) exceed its long term liabilities ($414.5K).


Debt to Equity History and Analysis

Debt Level: 366's debt to equity ratio (60.8%) is considered high.

Reducing Debt: 366's debt to equity ratio has increased from 42% to 60.8% over the past 5 years.


Balance Sheet

Inventory Level: 366 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 366's debt is covered by short term assets (assets are 1.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 366 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 366 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -37.1% each year


Next Steps

Dividend

What is AzurRx BioPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 366's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 366's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 366's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 366's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 366's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

James Sapirstein (58yo)

0.3yrs

Tenure

US$687,487

Compensation

Mr. James R. Sapirstein, R.Ph., M.B.A. serves as the President, Chief Executive Officer and Non-Independent Director of AzurRx BioPharma, Inc. since October 8, 2019. Mr. Sapirstein has been Executive Chair ...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD687.49K) is above average for companies of similar size in the German market ($USD412.50K).

Compensation vs Earnings: Insufficient data to compare James's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
James Sapirstein
CEO, President & Non-Independent Director0.3yrsUS$687.49kno data
James Pennington
Chief Medical Officer1.8yrsUS$441.43kno data
Martin Krusin
Vice President of Finance & Business Development6.1yrsno datano data
Daniel Schneiderman
Chief Financial Officer0.08yrsno data0.0037% $869.4
Mathieu Schué
Head of Laboratory0yrsno datano data

1.0yrs

Average Tenure

58yo

Average Age

Experienced Management: 366's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
James Sapirstein
CEO, President & Non-Independent Director0.3yrsUS$687.49kno data
Charles Casamento
Independent Director2.9yrsUS$108.74k0.35% $81.8k
Alastair Riddell
Independent Director4.4yrsUS$108.74k0.37% $87.0k
Edward Borkowski
Independent Chairman of the Board4.4yrsUS$108.74k1.63% $380.8k
Vern Schramm
Independent Director2.3yrsUS$108.74k0.25% $58.7k
Johan Spoor
Non-Independent Director5.8yrsUS$847.82k2.25% $524.9k
Philip Toskes
Member of Scientific Advisory Board0yrsno datano data
Fréderic Carrière
Member of Scientific Advisory Board0yrsno datano data
René Laugier
Member of Scientific Advisory Board0yrsno datano data
Mark Lowe
Member of Scientific Advisory Board0yrsno datano data

3.7yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 366's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.8%.


Top Shareholders

Company Information

AzurRx BioPharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AzurRx BioPharma, Inc.
  • Ticker: 366
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$25.155m
  • Listing Market Cap: US$23.309m
  • Shares outstanding: 26.80m
  • Website: https://www.azurrx.com

Number of Employees


Location

  • AzurRx BioPharma, Inc.
  • Downstate Biotechnology Incubator
  • Suite 304
  • Brooklyn
  • New York
  • 11226
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AZRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2016
366DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2016

Biography

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of therapeutic proteins under development, including MS1819-SD, a yeast derived recombinant lipase for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase enzyme combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea, as well as AZX1103, a b-lactamase enzyme combination. The company was incorporated in 2014 and is headquartered in Brooklyn, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:42
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.